Kenvue says post-hoc Phase III analysis links earlier 5% minoxidil use to higher hair regrowth in men with androgenetic alopecia

• Kenvue outlined new clinical and preclinical findings slated for presentation at the EADV Congress in Vienna from Sept. 30 to Oct. 3, 2026.
• Neutrogena studies indicated its niacinamide-based sunscreens improved visible acne-related marks and hydration, supporting broader multifunctional positioning in suncare.
• Aveeno data suggested colloidal oat formulations helped reinforce skin-barrier recovery, with clinician feedback supporting add-on use in eczema care.
• Regaine analysis linked earlier use of 5% minoxidil foam with stronger hair regrowth outcomes, supporting earlier-intervention messaging in male hair loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kenvue Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260930489298) on September 30, 2026, and is solely responsible for the information contained therein.